Rationale for Use of an FDA-Cleared Delivery System for Administration of Inhaled Nitric Oxide in Patients Undergoing Magnetic Resonance Imaging
Mauro Salas,1 Jim L Potenziano,2 Jaron Acker3 1Clinical Specialist, Children’s National Health System, Washington, DC, USA; 2Scientific Affairs, Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA; 3Medical Device Marketing, Mallinckrodt Pharmaceuticals, Bedminster, NJ, USACorrespondence: Ma...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/af2e74d420c64066a3143b344d1e16f1 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|